Alector (United States)

Recent papers from Alector (United States)

1. TDP-43–Associated Neurodegenerative Disease Conceptualization and Integrated StagingJAMA Neurology · 2026
2. Efficacy and Safety Results of INFRONT-3: A Phase 3 Randomized, Double-Blind, Placebo Controlled Study Evaluating Latozinemab (AL001) in FTD-GRN (LS2.002)Neurology · 2026
3. Feasibility and durability of a first-of-a-kind, sustainable biologic paint using bacterial pigment and protein binderJournal of Coatings Technology and Research · 2026
4. The proportional treatment effect: A metric that empowers and connectsJournal of Biopharmaceutical Statistics · 2025
5. Measuring neurofilament light in human plasma and cerebrospinal fluid: a comparison of five analytical immunoassaysClinical Chemistry and Laboratory Medicine (CCLM) · 2025
6. Development of AL101 (GSK4527226), a progranulin-elevating monoclonal antibody, as a potential treatment for Alzheimer’s diseaseAlzheimer s Research & Therapy · 2025
7. ICH E9(R1) Addendum 5-Year Anniversary – Where Are We with Its Implementation and Where to Go Next?Statistics in Biopharmaceutical Research · 2025
8. Integrative analysis of pooled CRISPR screens provide functional insights into AD GWAS risk genes2025
9. Harnessing greater statistical power: Comprehensive evaluation of disease modifying treatment effects across all or multiple post-baseline visits compared to the last visit for Alzheimer's disease clinical trialsJournal of Alzheimer s Disease · 2025
10. Myristoylation of TMEM106B by NMT1/2 regulates TMEM106B trafficking and turnoverJournal of Biological Chemistry · 2025
11. Measuring neurofilament light in human plasma and cerebrospinal fluid: a comparison of five analytical immunoassays2025
12. Harnessing Greater Statistical Power: Comprehensive Evaluation of Disease Modifying Treatment Effects Across All or Multiple Post-Baseline Visits Compared to the Last Visit for Alzheimer’s Disease Clinical Trials2025
13. The Proportional Treatment Effect: A Metric That Empowers and Connects2025
14. Advancing precision psychiatry and targeted treatments: Insights from immunopsychiatryBrain Behavior and Immunity · 2025
15. Enhancing gene set overrepresentation analysis with large language modelsBioinformatics Advances · 2024
16. The Alzheimer’s Disease Risk Genes MS4A4A And MS4A6A Cooperate to Negatively Regulate Trem2 and Microglia states2024
17. Enhancing Gene Set Overrepresentation Analysis with Large Language Models2024
18. Targeting TREM2 signaling shows limited impact on cerebrovascular calcificationLife Science Alliance · 2024
19. Preclinical and first-in-human evaluation of AL002, a novel TREM2 agonistic antibody for Alzheimer’s diseaseAlzheimer s Research & Therapy · 2024
20. Trem2 Agonist Reprograms Foamy Macrophages to Promote Atherosclerotic Plaque Stability—Brief ReportArteriosclerosis Thrombosis and Vascular Biology · 2024